1. Home
  2. ATHA vs KDLY Comparison

ATHA vs KDLY Comparison

Compare ATHA & KDLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATHA
  • KDLY
  • Stock Information
  • Founded
  • ATHA 2011
  • KDLY 2019
  • Country
  • ATHA United States
  • KDLY United States
  • Employees
  • ATHA N/A
  • KDLY N/A
  • Industry
  • ATHA Medicinal Chemicals and Botanical Products
  • KDLY
  • Sector
  • ATHA Health Care
  • KDLY
  • Exchange
  • ATHA Nasdaq
  • KDLY NYSE
  • Market Cap
  • ATHA 21.0M
  • KDLY 19.6M
  • IPO Year
  • ATHA 2020
  • KDLY 2024
  • Fundamental
  • Price
  • ATHA $0.43
  • KDLY $2.47
  • Analyst Decision
  • ATHA Buy
  • KDLY
  • Analyst Count
  • ATHA 4
  • KDLY 0
  • Target Price
  • ATHA $11.25
  • KDLY N/A
  • AVG Volume (30 Days)
  • ATHA 210.5K
  • KDLY 13.0M
  • Earning Date
  • ATHA 03-04-2025
  • KDLY 03-04-2025
  • Dividend Yield
  • ATHA N/A
  • KDLY N/A
  • EPS Growth
  • ATHA N/A
  • KDLY N/A
  • EPS
  • ATHA N/A
  • KDLY N/A
  • Revenue
  • ATHA N/A
  • KDLY $2,875,400.00
  • Revenue This Year
  • ATHA N/A
  • KDLY N/A
  • Revenue Next Year
  • ATHA N/A
  • KDLY N/A
  • P/E Ratio
  • ATHA N/A
  • KDLY N/A
  • Revenue Growth
  • ATHA N/A
  • KDLY N/A
  • 52 Week Low
  • ATHA $0.41
  • KDLY $0.65
  • 52 Week High
  • ATHA $4.21
  • KDLY $5.25
  • Technical
  • Relative Strength Index (RSI)
  • ATHA 34.62
  • KDLY N/A
  • Support Level
  • ATHA $0.42
  • KDLY N/A
  • Resistance Level
  • ATHA $0.46
  • KDLY N/A
  • Average True Range (ATR)
  • ATHA 0.04
  • KDLY 0.00
  • MACD
  • ATHA -0.00
  • KDLY 0.00
  • Stochastic Oscillator
  • ATHA 10.85
  • KDLY 0.00

About ATHA Athira Pharma Inc.

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.

About KDLY KINDLY MD INC

Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.

Share on Social Networks: